Thromboembolism in a patient with transient eosinophilia.
We report here a case of thromboembolism occurring in a 29-year-old woman with transient eosinophilia. Eosinophilia for at least 11 days was followed by pulmonary embolism. Both reperfusion of pulmonary arteries and disappearance of deep vein thrombi were obtained by treatment with urokinase, tissue plasminogen activator, and heparin. Although the causes of eosinophilia were not specified, we suggested a causative correlation of elevated serum levels of eosinophil granule proteins with the development of thromboembolism.
Mukai
H Y
HY
Division of Hematology, Institute of Clinical Medicine, University of Tsukuba, Japan.
Ninomiya
H
H
Mitsuhashi
S
S
Hasegawa
Y
Y
Nagasawa
T
T
Abe
T
T
D000328:Adult; D001798:Blood Proteins / Q000378:metabolism; D001991:Bronchitis / Q000097:blood / Q000150:complications; D004211:Disseminated Intravascular Coagulation / Q000188:drug therapy / Q000209:etiology; D004359:Drug Therapy, Combination; D047091:Eosinophil Granule Proteins; D004802:Eosinophilia / Q000097:blood / Q000150:complications*; D004804:Eosinophils / Q000378:metabolism; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000209:etiology*; D012260:Ribonucleases; D013924:Thrombophlebitis / Q000188:drug therapy / Q000209:etiology*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014859:Warfarin / Q000627:therapeutic use
D001798:Blood Proteins; D047091:Eosinophil Granule Proteins; D014859:Warfarin; D006493:Heparin; D012260:Ribonucleases; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator